This triple mechanism of action distinguishes retatrutide from existing approved therapies such as semaglutide (a GLP-1 receptor agonist) or tirzepatide (a dual GIP/GLP-1 agonist)
Exercise without overdoing it Movement supports hormone balance, but the wrong kind of overload can backfire
Previous studies reported that patients treated with semaglutide have reduced intensity of desire for sweet, savory, and salty foods, Jensterle Sever told Medical News Today, adding that the recent study is a proof-of-concept study, meaning that its an early-stage trial that strives to understand a specific concept, not confirm a certain phenomenon
By slowing gastric emptying and enhancing insulin sensitivity and glucose metabolism, oral tablets help regulate high blood sugar while improving glycemic control
The before is where you are today
Mortality in sickle cell disease